BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

MASH / NASH clinical trials and catalysts

Active industry-sponsored trials on ClinicalTrials.gov for nonalcoholic steatohepatitis: 65 (43 sponsors; 7 newly posted in the last 180 days, 2 stopped in the last 180 days; 0 new-entrant sponsors). Momentum score 22.3, rank 20 of 91 on the disease-area ranking. As of 2026-11-18.

Phase distribution: Early Phase 1 0, Phase 1 8, Phase 2 20, Phase 3 21, Phase 4 1, N/A 15.

Most active sponsors, by phase

SponsorActive trialsBy phaseNew (window)Upcoming readouts
Akero Therapeutics, Inc3P3 300
Boehringer Ingelheim3P3 310
Madrigal Pharmaceuticals, Inc. MDGL3P3 302
GlaxoSmithKline4P3 2, P2 1, P1 100
Hoffmann-La Roche2P3 200
Regeneron Pharmaceuticals REGN7P3 1, P2 630
Novo Nordisk A/S NVO2P3 1, P1 101
Zhejiang Doer Biologics Co., Ltd.2P3 1, P2 110
Eli Lilly and Company LLY1P3 100
Green Cross Wellbeing1P3 100
Haisco Pharmaceutical Group Co., Ltd.1P3 100
Innovent Biologics (Suzhou) Co. Ltd.1P3 101
Inventiva Pharma IVA1P3 100
Eccogene3P1 2, P2 122
Perspectum2NA 200
Wuxi Hisky Medical Technology Co Ltd2NA 200
1Globe Health Institute1P1 100
AB Biotics, SA1P2 101
AstraZeneca AZN1P2 101
Bioagile Therapeutics Pvt. Ltd.1NA 100
Boryung Pharmaceutical Co., Ltd1NA 101
Changchun Intellicrown Pharmaceutical Co. LTD1P1 100
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.1P2 101
ContextVision AB1NA 100
E-Scopics1NA 100

Recently stopped trials

Upcoming trial readouts (next 90 days)

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-12 est.P3Madrigal Pharmaceuticals, Inc. MDGLNCT05500222 A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)NASH; Cirrhosis, Liveractive not recruiting845
2026-12 est.P2Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.NCT06569524 Efficacy and Safety of Recombinant Human FGF21-Fc Fusion Protein for Injection (TQA2225/AP025) in Adult Subjects With Non-alcoholic Steatohepatitis (NASH)Non-alcoholic Steatohepatitisrecruiting120
2026-12-31 est.P2MediciNova MNOVNCT05464784 MN-001 in Non-alcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus, and HypertriglyceridemiaDiabetes Mellitus, Type 2; Hypertriglyceridemia; Non-Alcoholic Fatty Liver Diseaseactive not recruiting40
2026-12-31 est.P3Innovent Biologics (Suzhou) Co. Ltd.NCT06884293 A Study Comparing IBI362 vs Semaglutide in Chinese Overweight or Obese Adults With Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD)Overweight; Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD)active not recruiting479
2027-02 est.P2Rivus Pharmaceuticals, Inc.NCT07491458 A Trial to Investigate Safety, Exposure, and Efficacy of HU6 Compared With Placebo in Adult Participants With Metabolic Dysfunction-associated Steatohepatitis (MASH - Metabolic Dysfunction-Associated Steatohepatitisrecruiting180
2027-02-01 est.P2AB Biotics, SANCT07193927 Investigation of the Efficacy of a Probiotic Mixture in Moderate Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Mechanistic TrialMASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease; Fatty Liver Disease, Nonalcoholic;recruiting60
2027-02-14 est.P2Hudson BiotechNCT07481734 Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver DiseaseMetabolic Associated Steatotic Liver Disease; Nonalcoholic Steatohepatitis; Hepatic Steatosisrecruiting120

Readouts in the last 180 days

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-09-29P3Inventiva Pharma IVANCT04849728 A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 anNASH - Nonalcoholic Steatohepatitisactive not recruiting1000
2026-09-23P2Innovent Biologics (Suzhou) Co. Ltd.NCT06937749 A Study of IBI362 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH)Metabolic Dysfunction-associated Steatohepatitis (MASH)active not recruiting181
2026-08-13 est.P2Hinova Pharmaceuticals Inc.NCT07308548 A Trial to Evaluate the Efficacy, Safety, PK, and PD of HP515 in Non - Alcoholic Fatty Liver Disease ( NASH/MASH )NAFLD (Non-alcoholic Fatty Liver Disease)recruiting80
2026-08-03P2Merck Sharp & Dohme LLC MRKNCT06465186 A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017)Non-alcoholic Fatty Liver Disease; Nonalcoholic Steatohepatitis; NAFLD; Metabolic Dysfunction-associcompleted85
2026-07 est.P2Visirna Therapeutics HK LimitedNCT06322628 A Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of VSA006 in Chinese NASH PatientsNashactive not recruiting48
2026-06-26P2Hanmi Pharmaceutical Company Limited HAFCNCT04505436 Efocipegtrutide (HM15211) in Adults With Biopsy-Confirmed Nonalcoholic Steatohepatitis (NASH)NASH - Nonalcoholic Steatohepatitiscompleted215
2026-06-18P2Zhejiang Doer Biologics Co., Ltd.NCT07024212 Phase II Study Evaluating the Efficacy and Safety of DR10624 Injection in MASLD and MetALD SubjectsMASLDactive not recruiting110
2026-06-16 est.P2Guangdong Raynovent Biotech Co., LtdNCT05692492 A Randomized, Double-blind, Placebo-controlled Study of ZSP1601 in Adult Subjects With Nonalcoholic Steatohepatitis (NASH)Nonalcoholic Steatohepatitis (NASH)active not recruiting180
2026-06 est.P3Sagimet Biosciences Inc. SGMTNCT06692283 A Phase 3 Study Evaluating the Safety and Efficacy of Denifanstat in Patients With MASLD and MASHMASLD; MASH; NASH; Metabolic Dysfunction-Associated Steatotic Liver Disease; Metabolic Dysfunction-Awithdrawn

Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "nonalcoholic steatohepatitis"); readouts matched by condition text. Registry counts only; not a forecast.

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.